Covista Inc. (CVSA): what the price requires

At today's price, Covista Inc. (CVSA) is priced for -0.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/CVSA

Headline

FieldValue
TickerCVSA
CompanyCovista Inc.
Current price$133.54/sh
CompositionTuition and fees 99% / Other 1%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed3.1%
Operating margin today19.7%
Margin compression implied-16.6pp
Implied growth-0.4%
Multiple paid14x operating income

The operating-margin requirement is derived from the framework's value band at year 11, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 8.4% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6pp.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.28σ
cohort percentile (of 212 peers)27
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.78x5expensive
Earnings1.79x5expensive
Relative1.08x5expensive
Growth0.54x3justifies

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.2%); the inversion above states its own rate.

Per-Model Detail (n=18)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$379.480.35xyesFCF base $0.4B, growth 10% (input: historical growth), terminal g 4.0%, WACC 8.2%, 6yr projection
DCF Exit MultipleGrowth$245.230.54xyesExit EV/EBITDA: 10.8x / 12.8x / 14.8x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$128.351.04xyesP/E 18x (static sector reference · 2026-04), scenarios: 15.0x / 18.0x / 21.0x (bear / base = reference held flat / bull), EV/EBITDA 12x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$72.751.84xyesBV/sh $39.22, ROE (TTM) 17.2%, ke 9.3%
Two-Stage Excess ReturnAsset$97.801.37xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$158.890.84xyesRev $1.9B, growth 10% (input: historical growth; tapered), Terminal P/S: 2.0x / 2.4x / 2.8x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$76.921.74xyesEPS $6.41, growth 10% (input: historical EPS growth), PEG=1.99 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$62.592.13xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.24B × (1−26%) / WACC 8.2% → EPV (no growth)
Residual IncomeAsset$98.191.36xyesBV $39.22 + 5yr PV of (ROE (TTM) 17.2% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$75.211.78xyes√(22.5 × EPS $6.41 × BVPS $39.22) — Graham's conservative floor
EV/EBITDA RelativeRelative$123.681.08xyesEBITDA $0.41B × sector EV/EBITDA 12.0x
FCF YieldEarnings$87.471.53xyesFCF $336.3M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$74.571.79xyesSBC-adj FCF $0.29B (FCF $0.34B − SBC $0.04B) capitalized at Kₑ
Ben Graham FormulaEarnings$152.630.87xyesEPS $6.41 × (8.5 + 2×10.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$16.678.01xyesBV $39.22 × (ROIC 3.5% / WACC 8.2%)
P/Sales SectorRelative$137.270.97xyesRevenue $1.91B × sector P/S 2.5x
PEG Fair ValueRelative$95.721.40xyesEPS $6.41 × (PEG 1.5 × growth 10.0% (input: historical EPS growth)) → PE 14.9x
Earnings YieldEarnings$69.301.93xyesEPS $6.41 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$352.5m
Net debt / NOPAT (after-tax)1.25x
Net debt / operating income (pre-tax)0.93x
Interest coverage7.8x
Share count CAGR (buyback)-8.4%
Burning cashno

Bullet Takeaways

Bull Case

Start with what a standard earnings multiple does not capture here. At a little over $119 a share against trailing earnings near $6.41, Covista looks like an ordinary mid-cap trading around 18 times earnings. What that framing misses is the nature of the cash flow underneath it. This is a tuition business where students enroll in multi-year nursing, medical, and veterinary programs, then stay enrolled across many semesters. Revenue is recurring in the way few education names are, because a student halfway through a four-year pre-licensure BSN does not shop around each term. The company crossed 100,000 total students, with Walden posting its eleventh straight quarter of total enrollment growth and Chamberlain delivering the highest enrollment in its history. That is a back book that keeps refilling itself: a student two years into a four-year program is already most of next year's revenue.

The demand behind it is not cyclical, it is demographic. The United States has a documented, multi-year shortage of nurses and other clinicians, and Covista's institutions exist specifically to graduate them. When a hospital system cannot hire enough nurses, the bottleneck is upstream at the schools that train them, and Covista operates the largest such network. That structural pull is why enrollment kept climbing through a period when much of for-profit education shrank. It also explains the returns: a 17.2% return on equity and a 19.1% operating margin on roughly $1.91 billion of revenue are the economics of a business with pricing power and high incremental margins on each additional seat filled.

Management is using the cash the way a confident operator does. Free cash flow ran about $336 million, debt sits at less than a year of operating profit, and interest is covered nearly eight times over. Meanwhile the share count has fallen about 8.4% a year, which is buyback deployment showing up where it cannot be faked. A company retiring shares this steadily, while raising its full-year revenue outlook to $1.93 to $1.945 billion, is telling you where management thinks the value is. Each share repurchased at today's multiple claims a larger slice of an enrollment base that is still growing.

Bear Case

The valuation methods disagree sharply about Covista, and the disagreement is the bear case. Group them by what they look at. The asset-value and earnings-power methods, the ones that ask what the business is worth on its book equity and its current sustainable profit, land well below today's price: book value plus excess returns, the Graham floor, and earnings-power value all sit at a fraction of $119 (June 27, 2026), several of them below $100. Only the forward-growth methods and the peer-multiple lens reach the price, and they reach it by crediting growth that has to keep coming. When the conservative methods and the optimistic methods diverge this far, the conservative ones are usually the more honest read on what you own today, because they are not borrowing from a future that has not arrived.

What the price requires is durability, not a heroic growth rate. Inverting today's price, the market is paying roughly twelve times company-wide operating profit, an assumption the company can clear at its recent pace. The stretch is in how long that pace persists, not how fast it runs. And the single largest threat to persistence is not competitive, it is regulatory. Essentially all of Covista's revenue depends on students using federal Title IV aid to pay tuition. That makes the thesis hostage to Washington: changes to gainful-employment standards, the 90/10 rule, borrower-defense rules, loan caps, or the political appetite for funding for-profit and online education all flow straight to enrollment and revenue. This is an external variable with more leverage on the outcome than anything on the income statement, and the current price does not appear to discount it.

The balance sheet adds a second qualifier. Covista carries about $352 million of net debt and roughly $499 million of gross debt, so this is not a fortress that can absorb a demand shock indefinitely. Coverage near eight times is comfortable today, but it is comfortable because enrollment and margins are at highs. If a regulatory tightening or a reversal in the nursing-hiring cycle pressured enrollment, the same operating leverage that powers the bull case works in reverse, and the debt that looks small against peak operating profit looks larger against a depressed one. The bear does not need the business to fail; it needs growth to slow while the price is still paying for it to continue.

Valuation

This report assigns no fair value and no price target. It works backward from the $119.16 price to ask what that price assumes, then measures how far it sits from each way of valuing the business.

The embedded assumption is modest on its face. At today's price the market is paying roughly twelve times company-wide operating profit, which implies company-wide operating growth of only about negative three percent a year over the next five years. That is well within what Covista has recently delivered, so the price is not betting on acceleration. It is betting on persistence: that the enrollment base of more than 100,000 students and the 19.1% operating margin hold up across the duration, not that they expand. The bet is about how long the current economics last, not how much better they get.

The methods split cleanly on whether that is already paid for. The asset-value lens, book value plus the present value of excess returns on a 17.2% return on equity and a $39.22 book value per share, and the earnings-power lens, normalized operating profit capitalized at the cost of capital, both land below the price. The peer-multiple lens is close, valuing the equity near the price at a sector earnings multiple around eighteen times and a sector enterprise multiple of twelve times EBITDA. Only the forward-growth methods, the cash-flow models that project the top line forward, sit comfortably above. Read together, the pattern says the price is supported by what the business earns and grows, but not cushioned by its assets or its zero-growth earnings power. There is little margin for disappointment in the static methods.

Solvency frames the downside. Net debt of about $352 million is under one year of operating profit, interest is covered roughly eight times, and free cash flow near $336 million funds both the debt service and a share count that has fallen about 8.4% a year. The balance sheet can carry the business comfortably at current enrollment. What it cannot do is make the price cheap on the conservative methods; that gap closes only if enrollment and margins keep delivering.

Catalysts

The most direct catalyst is enrollment momentum and the guidance built on it. For fiscal 2026 the company raised its revenue outlook to a range of $1.93 to $1.945 billion, citing record enrollment at both Chamberlain and Walden and total enrollment surpassing 100,000 students, up about 6.8% year over year. Chamberlain returned to positive total enrollment growth and posted the highest enrollment in its history, while Walden extended its streak of total enrollment growth into an eleventh consecutive quarter. The next quarterly enrollment and revenue print is the cleanest test of whether that momentum is intact.

The name itself is a recent event worth noting: the company rebranded from Adtalem Global Education to Covista Inc. in February 2026, a corporate identity change rather than a change in the underlying institutions, which remain Chamberlain University, Walden University, and the Ross medical and veterinary schools. For investors tracking the ticker, the financial history and SEC filings carry forward under the same entity.

The variable that overrides all of these is regulatory. Because tuition is funded almost entirely through federal student aid, any shift in Title IV rules, gainful-employment standards, or loan policy is a catalyst in either direction, and it operates on a political rather than an operational timeline. There is no fixed date to watch, which is precisely what makes it the hardest risk to price.

Peer Cohorts (Per Segment, With Filing Citations)

Chamberlain (reported)

Walden (reported)

Medical and Veterinary (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Covista fiscal Q3 2026 results release · company announcement, February 2026

View the full interactive CVSA report on boothcheck